US needs to look differently at public health preparedness, says former FDA commissioner Gottlieb
Speaking at CPHI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities
The ongoing coronavirus pandemic means the US will need to look at public health preparedness through the lens of national security and treat it on par with other kinds of national security threats, according to former US Food and Drug Administration Commissioner, Dr Scott Gottlieb on Tuesday.
Speaking at the hybrid CPHI North America event, Gottlieb said the pandemic had changed the course of history, reset the global order in many significant ways from a geopolitical standpoint, cost trillions of dollars and superseded all other national priorities for more than a year.
“We’re seeing the outsized impact that pathogens and pandemics can have and it means we have to reset how we look at these kinds of risks,” he told delegates.
Outlining the practical measures to tackle future healthcare crises, Gottlieb said the US needs to build different capacities.
“We clearly didn’t have the capacities we thought we had and that we certainty needed,” he said.
He said that the after US’ pandemic planning in 2003, which was focused on concern around H5N1 flu, the country invested in building out certain capacities such as cell-based manufacturing facilities for vaccines, as well as stockpiles and antivirals.
“What happened over time was those efforts atrophied and we didn’t continue to invest in keeping them ready,” he said. “We had this idea that we would create a warm base of preparedness when really what we needed was a hot base of preparedness. You can’t build a vaccine manufacturing plant and mothball it. You really need to be operating these things at scale; in part, because you need to be able to make continuing investments to keep facilities up to date and in part because the only way you can retain personnel to run these kinds of facilities and be ready to scale them up in the event of an emergency is to be operating them.”
He described the country’s prior focus on flu as a mistake: “Even after SARS and MERS came along and it was apparent that coronaviruses were on the march and represented a different kind of threat, we never pivoted our thinking; we never invested in broader capacities that looked beyond flu.”
To register for our four-week hybrid event, CPHI North America and to watch the full webinar on demand, click here.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Eli Lilly confirms Pennsylvania for US$3.5bn manufacturing site
The company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10th US manufacturing site announced since 2020.
-
News Drug Approvals from 2025 – Triumphs in the midst of challenges
The following infographic outlines key drugs that have been newly approved by the US FDA in 2025. -
News Johnson & Johnson completes acquisition of Halda Therapeutics
Acquisition brings an advanced, highly differentiated treatment for prostate cancer, strengthening Johnson & Johnson’s longstanding commitment to innovation in the disease. Lead asset demonstrates potential to overcome key resistance pathways ... -
News AI-powered therapy offers hope for rare familial polyposis
Recursion Pharmaceuticals has announced promising results from its ongoing early- to mid-stage trial evaluating its AI-powered treatment, REC-4881, for familial adenomatous polyposis (FAP).
-
News CPHI Podcast Series: From Patents to Public Health: The GLP-1 Journey
The latest episode of the CPHI Podcast Series delves into the future of obesity management globally, offering opinins on might happen after patent expirys and new globals players entering the fray.
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta...